Key Market Indicators
Sales of Swedish antihypertensive medicines are predicted to hit $40.6 million by 2026, up from $35.3 million in 2021. That's an average yearly growth rate of 2.6%. Since 2005, demand has increased by a yearly average of 7.4%. In 2021, Sweden was ranked 11th, with Hungary overtaking them at $35.3 million. Italy, Spain and Australia came in second, third and fourth respectively in the ranking.
